Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

RG7356, a recombinant anti-CD44 immunoglobulin G1 humanized monoclonal antibody, inhibits cell adhesion and has been associated with macrophage activation in preclinical models. We report results of a phase I dose-escalation study of RG7356 in relapsed/refractory acute myeloid leukemia (AML). Eligib...

Descripción completa

Detalles Bibliográficos
Autores principales: Vey, Norbert, Delaunay, Jacques, Martinelli, Giovanni, Fiedler, Walter, Raffoux, Emmanuel, Prebet, Thomas, Gomez-Roca, Carlos, Papayannidis, Cristina, Kebenko, Maxim, Paschka, Peter, Christen, Randolph, Guarin, Ernesto, Bröske, Ann-Marie, Baehner, Monika, Brewster, Michael, Walz, Antje-Christine, Michielin, Francesca, Runza, Valeria, Meresse, Valerie, Recher, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078031/
https://www.ncbi.nlm.nih.gov/pubmed/27081038
http://dx.doi.org/10.18632/oncotarget.8687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078031/
https://www.ncbi.nlm.nih.gov/pubmed/27081038
http://dx.doi.org/10.18632/oncotarget.8687

Ejemplares similares